KalVista licenses commercialisation rights for HAE to Kaken in Japan
KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...
Fierce Biotech4h
KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal
As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...
Innovations In Diabetes-Related Eye Care Drive Growth In Ophthalmic Treatment Market
Emergen Research Logo The development of anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina, reduces the ...
Medindia6h
AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd ...
Medical Dialogues10h
Topical Anti-Inflammatory Drugs Promising in Managing Diabetic Macular Edema: Systematic Review Finds
Diabetic macular edema remains a significant cause of vision loss in individuals with diabetes, often requiring invasive ...